Omeros Q1 2021 Earnings Report
Key Takeaways
Omeros Corporation reported first quarter 2021 financial results, with OMIDRIA revenues at $21.1 million. The company's net loss was $35.1 million, or $0.57 per share. As of March 31, 2021, Omeros had $100.5 million in cash, cash equivalents and short-term investments.
OMIDRIA revenues for Q1 2021 were $21.1 million.
Net loss in Q1 2021 was $35.1 million, or $0.57 per share.
Omeros had cash, cash equivalents and short-term investments of $100.5 million as of March 31, 2021.
Dosing of patients with narsoplimab in the I-SPY COVID-19 platform trial began in March 2021.
Omeros
Omeros
Forward Guidance
Omeros is progressing toward the anticipated launch of narsoplimab for TA-TMA and building momentum with OMIDRIA following CMS' confirmation of separate payment for OMIDRIA in the ASC setting.